Vandetanib Gemcitabine Or Placebo Plus Gemcitabine Or Vandetanib Monotherapy In Advanced Biliary Tract Cancer
Status:
Completed
Trial end date:
2012-09-01
Target enrollment:
Participant gender:
Summary
The primary objective of the trial is to determine the efficacy of VANDETANIB monotherapy or
VANDETANIB plus GEMCITABINE or PLACEBO plus GEMCITABINE in prolonging the progression-free
survival (PFS) at the trial closure in patients with advanced (unresectable or metastatic)
biliary tract cancer.